$211,409,788

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

ACTION DATE—·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50122C00047_7505_-NONE-_-NONE-

Award description

CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Research and development of smallpox antiviral treatments through Chimerix Inc partnership.

Sub-sectors

antiviral-developmentbiodefensesmallpox-countermeasures

Why this matters

Smallpox biodefense capability is critical strategic asset given pandemic preparedness and potential bioweapon threats.

Supply-chain signal

Signals investment in domestic antiviral manufacturing and pharmaceutical supply chain resilience for pandemic countermeasures.

U.S.–China competition angle

Reflects U.S. biodefense prioritization amid concerns over adversary biological capabilities and medical countermeasure independence.

Generated by award_classification v1.0.0 via claude-haiku-4-5-20251001 on 2026-05-13. Cost: $0.001358.

Period of performance

Start

2022-08-29

End

2028-10-01

Status

activein 871 days

Recipient

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_75A50122C00047_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.